OverviewSuggest Edit

PTC Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of orally-administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company's lead product, Translarna, is used for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients with age of over five years and older. Its programs include Translarna for nonsense mutation cystic fibrosis, Translarna for mucopolysaccharidosis type I caused by nonsense mutation, Translarna for nonsense mutation aniridia, and Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy in collaboration with Spinal Muscular Atrophy Foundation.
TypePublic
Founded1998
HQSouth Plainfield, NJ, US
Websiteptcbio.com
Employee Ratings3.7
Overall CultureA-

Latest Updates

Employees (est.) (Dec 2019)754(+48%)
Job Openings77
Revenue (FY, 2020)$380.8 M(+25%)
Share Price (Apr 2021)$45.8(-2%)
Cybersecurity ratingCMore

Key People/Management at PTC Therapeutics

Stuart Peltz

Stuart Peltz

CEO
Neil Almstead

Neil Almstead

Executive Vice President, Research, Pharmaceutical Operations & Technology
Mark Boulding

Mark Boulding

Executive Vice President and Chief Legal Officer
Mary Harmon

Mary Harmon

Senior Vice President, Corporate Relations
VMD Mark J. Pykett

VMD Mark J. Pykett

Chief Innovation Officer
Martin Rexroad

Martin Rexroad

Senior Vice President, Human Resources
Show more

PTC Therapeutics Office Locations

PTC Therapeutics has an office in South Plainfield
South Plainfield, NJ, US (HQ)
100 Corporate Ct
Show all (1)

PTC Therapeutics Financials and Metrics

PTC Therapeutics Revenue

PTC Therapeutics's revenue was reported to be $380.77 m in FY, 2020
USD

Revenue (FY, 2020)

380.8m

Net income (FY, 2020)

(438.2m)

EBIT (FY, 2020)

(431.8m)

Market capitalization (23-Apr-2021)

3.2b

Closing stock price (23-Apr-2021)

45.8

Cash (31-Dec-2020)

208.8m

EV

3.4b
PTC Therapeutics's current market capitalization is $3.2 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

34.7m25.2m36.8m82.7m194.4m264.7m307.0m380.8m

Revenue growth, %

(27%)46%125%

Cost of goods sold

4.6m12.7m12.1m

Gross profit

189.8m252.1m294.8m
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

6.9m16.3m9.2m1.7m1.7m7.5m6.8m9.8m18.9m15.6m23.0m26.5m48.0m41.9m56.1m68.7m53.6m53.6m85.5m71.4m68.3m75.2m118.4m

Cost of goods sold

39.0k758.0k1.6m3.0m2.6m3.3m2.4m3.2m3.0m

Gross profit

26.5m47.2m40.3m53.0m66.2m50.3m51.2m82.3m68.4m

Gross profit Margin, %

100%98%96%95%96%94%96%96%96%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

15.4m49.7m58.0m58.3m111.8m169.5m288.0m208.8m

Accounts Receivable

4.4m11.1m24.9m40.4m67.9m55.5m69.9m

Prepaid Expenses

1.6m3.9m5.9m6.7m9.2m17.9m39.5m

Inventories

4.7m10.8m16.1m19.3m18.7m
USDQ2, 2013

Financial Leverage

1.1 x
Show all financial metrics

PTC Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Agilis BiotherapeuticsJuly 20, 2018$200 m

PTC Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

75/100

SecurityScorecard logo

PTC Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

PTC Therapeutics Online and Social Media Presence

Embed Graph

PTC Therapeutics Company Culture

  • Overall Culture

    A-

    87/100

  • CEO Rating

    B

    75/100

  • Compensation

    A+

    100/100

Learn more on Comparably

PTC Therapeutics News and Updates

PTC Therapeutics Received Gallup's "Don Clifton Strengths-Based Culture" Award

SOUTH PLAINFIELD, N.J., April 7, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has been named a winner of the 2021 "Don Clifton Strengths-Based Culture Award" from Gallup. The award recognizes organizations with strong workplace cultures that get the...

PTC Therapeutics to Host PTC518 Huntington Disease Deep Dive Webinar

SOUTH PLAINFIELD, N.J., April 7, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing the PTC518 Huntington disease (HD) program on Thursday, April 15 at 9 a.m. E.T. The Huntington Disease Deep Dive will provide an overview of...

PTC Therapeutics Provides Update on R&D Pipeline and Commercial Progress at 39th Annual J.P. Morgan Healthcare Conference

SOUTH PLAINFIELD, N.J., Jan. 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its R&D pipeline and commercial progress at the 39th Annual J.P. Morgan Healthcare Conference today, Monday, Jan. 11 at 7:30 a.m. EST. Stuart W. Peltz, Ph.D., Chief...

CENTOGENE Expands Partnership with PTC Therapeutics to Generate New Insights for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency

Expanded Partnership Provides Free Biochemical and Genetic Testing to Patients Enrolled in REVEAL CP Study and Expands Global No-Cost Testing Program to Additional Countries Expanded Partnership Provides Free Biochemical and Genetic Testing to Patients Enrolled in REVEAL CP Study and Expands Global …

PTC Therapeutics Announces Initiation of a Registration-Directed Clinical Trial to Evaluate Vatiquinone in Mitochondrial Epilepsy

SOUTH PLAINFIELD, N.J., Oct. 26, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the initiation of a registration-directed Phase 2/3 clinical trial to evaluate vatiquinone (PTC743) in patients with mitochondrial epilepsy, the highly morbid condition of...

RareMed Solutions Announces that it has been Selected as the Non-Commercial Dispensing Pharmacy for EMFLAZA® by PTC Therapeutics, Inc.

PITTSBURGH, Oct. 21, 2020 /PRNewswire/ -- RareMed Solutions announces that it has been selected by PTC Therapeutics, Inc. to provide non-commercial dispensing services for the drug EMFLAZA® (deflazacort). RareMed will be the exclusive free drug provider for EMFLAZA®, managing the EMFLAZA®...
Show more

PTC Therapeutics Blogs

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2021 Financial Results

SOUTH PLAINFIELD, N.J. , April 20, 2021 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2021 financial results and provide an update on the company's business and outlook on Tuesday, May 4, 2021

Continued Improvements in Motor Milestones in Infants with Type 1 Spinal Muscular Atrophy After Two Years of Treatment with Evrysdi™

- Evrysdi increased survival and reduced need for permanent ventilation - SOUTH PLAINFIELD, N.J. , April 15, 2021 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that results from Part 2 of the pivotal FIREFISH trial demonstrated that infants with type 1 spinal muscular

PTC Therapeutics Launches the PTC Pinpoint Direct™ Program for Patient-Initiated Genetic Testing

PTC Therapeutics Launches the PTC Pinpoint Direct™ Program for Patient-Initiated Genetic Testing Content Import Wed, 04/14/2021 - 08:03 PTC Therapeutics Launches the PTC Pinpoint Direct™ Program for Patient-Initiated Genetic Testing Apr 14, 2021 This release i…

PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi™

PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi™ Content Import Thu, 04/01/2021 - 08:03 PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi™ Apr 1, 2021 …

PTC Therapeutics Announces the European Approval of Evrysdi™ for the Treatment of Spinal Muscular Atrophy

- First and only at home treatment approved for SMA - - Proven efficacy in adults and children with SMA 2 months and older - SOUTH PLAINFIELD, N.J. , March 30, 2021 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the European Commission (EC) has granted marketing

PTC Presents Results from a Real-World Study of Steroid Switching in the Treatment of Patients with Dystrophinopathies

- Desire to slow disease progression and tolerability issues were the primary reasons for switching from prednisone to EMFLAZA® (deflazacort) - - Delayed disease progression and improved benefit-risk reported during the 6-month average follow up after switching to EMFLAZA - SOUTH PLAINFIELD, N.J.
Show more

PTC Therapeutics Frequently Asked Questions

  • When was PTC Therapeutics founded?

    PTC Therapeutics was founded in 1998.

  • Who are PTC Therapeutics key executives?

    PTC Therapeutics's key executives are Stuart Peltz, Neil Almstead and Mark Boulding.

  • How many employees does PTC Therapeutics have?

    PTC Therapeutics has 754 employees.

  • What is PTC Therapeutics revenue?

    Latest PTC Therapeutics annual revenue is $380.8 m.

  • What is PTC Therapeutics revenue per employee?

    Latest PTC Therapeutics revenue per employee is $505 k.

  • Who are PTC Therapeutics competitors?

    Competitors of PTC Therapeutics include ReCode Therapeutics, Alembic Pharmaceuticals and Biocon.

  • Where is PTC Therapeutics headquarters?

    PTC Therapeutics headquarters is located at 100 Corporate Ct, South Plainfield.

  • Where are PTC Therapeutics offices?

    PTC Therapeutics has an office in South Plainfield.

  • How many offices does PTC Therapeutics have?

    PTC Therapeutics has 1 office.